TA
Tatva Chintan Pharma Chem Limited
TATVA.NS · NSE
₹1,678.50 +5.16% (+₹82.30)
1M -3.04%
Market Cap ₹37.4B
P/E Ratio 72.75x
Div. Yield -
ROE 6.69%
Piotroski F-Score Moderate
5/9Valuation
2 /100
Expensive P/E 72.75x
EV/EBITDA 33.38x
P/S 6.72x
Growth
23 /100
Declining EPS growth 62.03%
Rev. growth 4.08%
Book val. growth 16.02%
Profitability
60 /100
Moderate Gross margin 52.75%
Net margin 9.24%
Op. margin 12.53%
Quality
48 /100
Average ROE 6.69%
ROIC N/A
ROA N/A
Debt
100 /100
Low Debt/Equity 0.00x
Int. coverage 16.27x
Net debt/EBITDA 0.00x
Stability
75 /100
Stable Beta 0.42x
Rev. volatility 2.65%
EPS volatility 23.26%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o TATVA.NS
Online
Sector
Basic Materials
Industry
Chemicals - Specialty
CEO
Chintan Nitinkumar Shah
Employees
689
Headquarters
Vadodara
Prihajajoči dogodki
11 SEP.
Ex-Dividend
Ex-dividend date
01 OKT.
Dividend Payment
Datum plačila
30 OKT.
Earnings
Upcoming earnings report